Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

ARNA 4.31 -0.20 (-4.43%)
price chart
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Puts Another Treatment in the ...
New drugs may make or break a pharmaceutical competitor, so Arena Pharmaceutical Inc (NASDAQ:ARNA, ARNA message board) announced an addition to its research and development pipeline, a new treatment for pulmonary arterial hypertension.
Arena Pharma (ARNA), Vivus (VVUS): Which Hedge Funds Made the Wrong ...
Since the end of 2Q, the very popular biopharma companies, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) and Vivus, Inc. (NASDAQ:VVUS) have performed poorly.
Related articles »  
Sucampo Pharma: An Undervalued Biopharma With Upcoming Catalysts
Another recent example of a strong catalyst price moving event was when Arena Pharma (ARNA) saw its stock price rise from the low $2 range to over $3.50 a share before the ADCOM for its weight loss drug, Belviq, and a gap up in price from $3.66 to $7 ...
Now Could Be The Time To Speculate On Achillion Pharmaceuticals
That will cost Achillion a large percentage of all future profits (still not an awful deal at this point), just as Arena had to do.
FDA Considers Faster Approval Process for Obesity Drugs
Arena Pharmaceuticals Inc. (ARNA:US)'s Belviq weight-loss pill and Vivus Inc. (VVUS:US)'s Qsymia may have been approved earlier for use by morbidly obese people had such a path existed.
Related articles »  
3 Best Biotech Stocks For This Week (Part VII)
... symptomatic neurogenic orthostatic hypotension. So in this article, I will write about the reasons to take a speculative position in Cell Therapeutics Inc (NASDAQ:CTIC), Arena Pharmaceuticals (NASDAQ:ARNA) and Chelsea Therapeutics (NASDAQ:CHTP).
Vivus Pharmaceuticals (NASDAQ:VVUS) Falls on Readjusted Sales Expectations
The drug also comes out with a warning on cardio-vascular risks as the company has not completed the trials to prove safety. Competitor Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is just starting a post-market trial to assess heart and lung risk of the drug.
Related articles »  
NPS Pharmaceuticals: Buy If There Is A Dip
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares were up nearly 20% on news that the FDA briefing document may favor approval of Gattex.
Related articles »  
Orexigen talks FDA on speeding Contrave review
Orexigen is looking for ways to quicken the application process for Contrave, and the company said the FDA is open to discussing options.
Related articles »  
Investors Neglect Solazyme's Leadership In Industrial Biotechnology
As a result, the non-product revenues remains much akin to pharmaceutical companies and their milestone payments such as that seen with Arena Pharmaceutical (NASDAQ:ARNA) and its relationship with Eisai Inc. As is the case with many of these ...
Related articles »